ArticleScientific reports2024
DCLRE1B as a novel prognostic biomarker associated with immune infiltration: a pancancer analysis.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The DNA cross-link repair 1B (DCLRE1B) gene is involved in repairing cross-links between DNA strands, including those associated with Hoyeraal-Hreidarsson syndrome and congenital dyskeratosis. However, its role in tumours is not well understood. DCLRE1B expression profiles were examined in tumour tissues and normal tissues using TCGA, GTEx, and TARGET datasets. Additionally, we performed experiments with clinical melanoma samples to verify DCLRE1B expression patterns. We also performed pancancer analyses to investigate the diverse roles of DCLRE1B in the biological functions of various cancers. DCLRE1B exhibited distinct expression patterns and played crucial prognostic roles in most tumours. In particular, high expression of DCLRE1B in melanoma was significantly correlated with a poor prognosis and increased malignancy. DCLRE1B was also found to be associated with the immune landscape and various immune biomarkers and regulators. Furthermore, our analysis identified potential small molecules that could target DCLRE1B in different cancer types. The DCLRE1B gene may be involved in the development and occurrence of a variety of cancers. Additionally, DCLRE1B affects various tumour types not only by mediating DNA repair but also by shaping the differential immune microenvironment. In conclusion, our research offers fresh perspectives on the diagnosis and treatment of different types of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.